Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2025.05.07.652451

Hematopoietic Stem Cells Modulate Tumor Immune-Environment to Target Triple-Negative Breast Cancer via Altering Mitochondrial Bioenergetics

Bose, B.·Mallick, S.·Biswas, S.·Shenoy, S. P.
View original source ↗Export metadata ↓

Abstract

Ontogenic development of Hematopoietic stem cells (HSCs) takes place at diverse anatomical niches. Moreover, during embryonic development, HSCs migrate from the aorta-gonad mesonephros (AGM) to the fetal liver and finally to the bone marrow immediately after childbirth. Hence, the primary residence of adult HSCs in the bone marrow continues replenishing the hematopoietic lineage pool. In vivo, the HSC niche is significant and might be harnessed in regenerative medicine. HSCs in various niches have exhibited their respective tropism and proliferations based on the growth factors secreted by the niche. Accordingly, in this work, we hypothesized HSCs tropism towards cancer and stem cell niche of triple-negative breast cancer (TNBC) and HER2+, having a high relapse rate for possible cell therapy development. Our results indicate that HSC exclusive tropism towards breast cancer stem cells (CSC) and interaction with the cancer milieu lead to HSC differentiation into T-lymphocyte cells (CD4 & CD8). Moreover, the single-cell type proteomics of the migrated HSCs towards TNBC-CSCs and HER2+ cells indicated upregulation of IL-7 and Notch protein and several other upregulated proteins primarily involved in T cell activation and migration-related pathways. Likewise, the metabolomics from HSCs-derived conditioned media-treated CSCs, and HER2+ cells showed the capability of HSC-CM in arresting the growth and cell cycle of TNBC-CSC via altered mitochondrial bioenergetics. Hence, this study paves the way toward harnessing the potential of both HSCs and HSC-CM for personalized medicine against TNBC CSCs. HighlightsO_LIHematopoietic stem cells exhibited tumor tropism towards triple negative breast cancer stem cells and HER2+ cancer cells. C_LIO_LIUpon migration in the tumor milieu, HSCs differentiated into T cells, targeted CSCs, and modulated the upregulation of interleukin-7 and notch proteins. C_LIO_LIHSCs-CM inhibited the cell cycle in TNBC-CSCs by downregulating CDK1, disrupting mitochondrial bioenergetics via upregulated Drp1, and inducing CSC apoptosis. C_LIO_LIParacrine signaling from HSCs via conditioned media induced metabolic stress and disrupted key metabolic pathways in TNBC-CSCs. C_LI SummaryHematopoietic stem cells (HSCs) are known for their regenerative potential in the blood system. This study reveals the novel therapeutic potential of hematopoietic stem cells (HSCs) in combating triple-negative breast cancer stem cells (TNBC-CSCs). HSCs exhibited tropism towards TNBC-CSCs, themselves differentiated into T cells within the tumor microenvironment, leading to targeted cell killing of TNBC-CSCs. In addition, paracrine signaling from HSC-conditioned media (CM) induced metabolic stress in TNBC-CSCs and disrupted key metabolic pathways. HSC-CM also disrupted mitochondrial dynamics and function, leading to DNA damage and apoptosis. Critically, HSC-CM impaired TNBC-CSC stemness by downregulating stemness genes, leading to the inhibition of 3D spheroid formation. Hence, our study highlights HSCs as a promising therapeutic strategy for targeting TNBC-CSCs via disrupted metabolic homeostasis and self-renewal.

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Bose, B., Mallick, S., Biswas, S., Shenoy, S. P.. 2025-05-10. Hematopoietic Stem Cells Modulate Tumor Immune-Environment to Target Triple-Negative Breast Cancer via Altering Mitochondrial Bioenergetics. https://doi.org/10.1101/2025.05.07.652451

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Tet2-Clonal Hematopoiesis Promotes Whereas Dnmt3a-CH Inhibits Breast Cancer Progression During Aging

Clonal hematopoiesis of indeterminate potential (CHIP) driven by somatic mutations in blood cells increases with age and is associated with adverse outcomes in cancer patients. How CHIP mutations influence solid tumor progression remains unclear. Using inducible murine models of Dnmt3a- or Tet2-mutant CHIP combined with orthotopic syngeneic breast cancer models, we demonstrate that upon aging Dnmt3a-mutant CHIP prevents whereas Tet2-mutant CHIP drives breast cancer progression. Dnmt3a-mutant immune infiltrates established interferon-mediated MHCIIhigh tumor-associated macrophages (TAMs) that supported cytotoxic CD8+ T cell-mediated tumor rejection. In contrast, Tet2-mutant TAMs exhibited an inflammatory, immunosuppressive phenotype characterized by increased IL-1 and CXCL2 production, reduced MHCII expression, and impaired T cell recruitment and activation. Therapeutic blockade of IL-1R1 or CXCR2 reduced tumor progression in aged Tet2-mutant CHIP mice and partially restored anti-tumor immunity. These findings establish that the effects of CHIP on cancer are mutation- and age-dependent and identify IL-1/CXCL2-driven inflammation as a therapeutic vulnerability of tumor-promoting Tet2-mutant CHIP.

cancer biology↗
bioRxiv2026

Single Nucleus Profiling Reveals Rewired Tumor-Immune-Stromal Cell Communication in Plasmacytoid Urothelial Carcinoma

Plasmacytoid urothelial carcinoma (PUC) is an aggressive histologic subtype of bladder cancer associated with worse patient outcomes and therapeutic response compared to conventional urothelial carcinoma (CUC). While recent work has demonstrated metastatic lymph nodes from PUC tumors have an inflamed phenotype, how the tumor microenvironment (TME) and crosstalk between tumor, stromal, and immune cells in primary PUC bladder tumors differs from those in CUC remains poorly understood. The impact of these differences on response to immunotherapy is also unknown. To understand TME differences between CUC and PUC and their impact on cell signaling, we performed single nucleus RNA sequencing on PUC and CUC tumors, as well as Xenium spatial transcriptomics on a mixed CUC / PUC tumor. We identified increased signaling between PUC-enriched, CDH1-low urothelial cells, immunosuppressive lipid-associated macrophages, and SFRP2+/CTHRC1+ fibroblasts in PUC tumors compared to CUC. Spatial transcriptomics identified increased macrophage infiltration in PUC histology and colocalization of PUC tumor cells, immunosuppressive macrophages, and SFRP2+ fibroblasts. Taken together, this study delineates PUC architecture and demonstrates interplay CDH1-low tumor cells, EMT, and immunosuppressive macrophages, identifying possible therapeutic vulnerabilities in PUC.

cancer biology↗
bioRxiv2026

The Phospholipase A2 Activity of Peroxiredoxin 6 Protects Hepatocarcinoma Cells Against Ferroptosis and Mitophagy Impairment

Peroxiredoxin 6 (PRDX6) is a moonlighting protein that plays a key role in regulating redox homeostasis and lipid metabolism through its unique dual peroxidase and calcium-independent phospholipase A2 (iPLA2) activities. Here, we generated a stable HepG2 cell line harboring a D140A mutation to selectively ablate iPLA2 activity, and we compared its phenotype with that of wild-type (WT) and PRDX6-knockout (KO) cells. D140A exhibited low ROS leves, similar to WT cells, confirming that oxidative stress is due to peroxidase deficiency. In contrast, D140A cells displayed higher lipid peroxidation than WT cells, though significantly lower than that of KO cells. Furthermore, the D140A mutant mirrored the KO phenotype regarding intracellular ferrous iron accumulation, impaired lipid droplet biogenesis, and the downregulation of the key ferroptosis regulator GPX4. Mechanistically, integrated proteomic, lipidomic, and enzymatic analyses revealed that a deficiency in iPLA2 activity of PRDX6 disrupted the release of key lipid species necessary for cell structure and signaling. Consequently, organelles involved in lipid synthesis and trafficking, such as peroxisomes, endoplasmic reticulum, mitochondria and lipid droplet, were affected. Specifically, we found that mitochondria exhibited a reduction in cristae and a diminished capacity for mitophagy and autophagy, which ultimately makes cells much more susceptible to erastin-induced ferroptotic cell death. Taken together, our findings demonstrate that PRDX6 iPLA2 activity uniquely coordinates organelle lipid homeostasis and mitophagy to protect cancer cells from ferroptotic cell death. Consequently, the use of iPLA2 inhibitors such as MJ33, which decreased PRDX6 iPLA2 activity to a level comparable to the mutant D140A, could represent a promising therapeutic strategy for inducing ferroptotic cell death in hepatocellular carcinoma.

cancer biology↗